Skip to content

ShOckwave ballooN or Atherectomy with Rotablation in calcified coronary artery lesions, the SONAR Trial. ;A randomized controlled trial comparing rates of peri-procedural myocardial infarction after intravascular ultrasound and rotational atherectomy in patients with calcified coronary artery lesions.

ShOckwave ballooN or Atherectomy with Rotablation in calcified coronary artery lesions, the SONAR Trial. ;A randomized controlled trial comparing rates of peri-procedural myocardial infarction after intravascular ultrasound and rotational atherectomy in patients with calcified coronary artery lesions. - the SONAR Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON53616
Enrollment
65
Registered
2023-04-03
Start date
2022-10-31
Completion date
Unknown
Last updated
2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severely calcified coronary arteries

Interventions

- Shockwave ballon - Rotablatie

Sponsors

UZ Leuven
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patient older than 18 years. The subject has stable or unstable angina pectoris, or a positive functional study for ischemia. The subject is eligible for PCI. The subject gives consent prior to study inclusion. The subject has a moderate to severe calcified lesion with the expected need of plaque modification, on the condition that with or without low profile balloon (= 2.5 non-compliant balloon can cross the lesion. The calcified lesion has a 50-90% diameter stenosis by angiographic assessment.

Exclusion criteria

Exclusion criteria: Previous and/or planned brachytherapy of target vessel. Pregnant and/or breast-feeding females or females who intend to become pregnant. Patients who intend to have a major surgical intervention within 6 months of enrolment in the study. Patients who previously participated in this study. Subject has experienced an acute myocardial infarction 72 hours prior to the index procedure, as defined either by the presence of a new Q-wave in 2 or more contiguous leads, or by a CK greater than two times site upper reference limit (URL) with presence of CK-MB greater than the site URL. The subject has suffered a stroke or transient ischemic neurological attack or cerebrovascular accident within the past six months, or has any known intracranial mass, arteriovenous malformation, aneurysm or other intracranial pathology. The subject has experienced a significant gastrointestinal or genitourinary bleed within the past six months, or has had any active bleeding within two months. Planned revascularization of target vessel within 1 year after index procedure. Lesions not ideal for Shockwave treatment: Longer than 40mm. The target vessel contains intraluminal thrombus. The subject has had a prior stent in the target lesion, including a 5mm zone proximal and distal to the lesion.

Design outcomes

Primary

MeasureTime frame
Primary outcome: difference in the rate of peri-procedural myocardial infarction (Type 4a of the universal Definition of Myocardial Infarction) in patients allocated to Shockwave IVL group versus RA group.

Secondary

MeasureTime frame
Secondary outcomes: in centres where the index of microcirculatory resistance (IMR) can be measured before and after PCI, a rate of peri-procedural microvascular dysfunction will be measured. Other secondary outcomes: peri-procedural myocardial injury (defined as a peak high sensitivity troponin T of >=0.014ng/mL); descriptive study of IMR measurements in calcified lesions; technical success (defined as a residual stenosis

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)